Table 1 Patient demographics
|  | Treatment group, 90 mg (n = 8) | Treatment group, 135 mg (n = 5) | Total (N = 13) |
|---|---|---|---|
Age, years | |||
 Mean (SD) | 50.3 (16.05) | 53.6 (9.56) | 51.5 (13.55) |
 Median | 49.5 | 56.0 | 50.0 |
 Min, Max | 26, 75 | 43, 66 | 26, 75 |
Age category, n (%) | |||
 18–60 years | 6 (75.0) | 4 (80.0) | 10 (76.9) |
 61–75 years | 2 (25.0) | 1 (20.0) | 3 (23.1) |
Male, n (%) | 3 (37.5) | 2 (40.0) | 5 (38.5) |
Female, n (%) | 5 (62.5) | 3 (60.0) | 8 (61.5) |
Race, n (%) | |||
 White | 7 (87.5) | 4 (80.0) | 11 (84.6) |
 Asian | 0 | 1 (20.0) | 1 (7.7) |
 Missing | 1 (12.5) | 0 | 1 (7.7) |
Ethnicity, n (%) | |||
 Hispanic or Latino | 2 (25.0) | 2 (40.0) | 4 (30.8) |
 Not Hispanic or Latino | 6 (75.0) | 3 (60.0) | 9 (69.2) |
ECOG performance status, Cycle 1/Day 1, n (%) | |||
 0 | 4 (50.0) | 2 (40.0) | 6 (46.2) |
 1 | 4 (50.0) | 3 (60.0) | 7 (53.8) |
Prior chemotherapy, n (%) | 5 (62.5) | 4 (80.0) | 9 (69.2) |
Prior TKI therapy, n (%) | 4 (50.0) | 3 (60.0) | 7 (53.8) |
Tumor type, n | |||
 GIST | 3 | 0 | 3 |
 Sarcoma | 2 | 1 | 3 |
 Thyroid cancer | 1 | 1 | 2 |
 Colorectal cancer | 1 | 1 | 2 |
 Gall bladder cancer | 0 | 1 | 1 |
 Melanoma | 1 | 0 | 1 |
 Unknown primary tumor | 0 | 1 | 1 |